LUSEFI Trademark

Trademark Overview

On Tuesday, July 23, 2019, a trademark application was filed for LUSEFI with the United States Patent and Trademark Office. The USPTO has given the LUSEFI trademark a serial number of 79266032. The federal status of this trademark filing is REGISTERED as of Tuesday, May 26, 2020. This trademark is owned by Taisho Pharmaceutical Co., Ltd.. The LUSEFI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use, namely, for the treatment of diabetes
lusefi

General Information

Serial Number79266032
Word MarkLUSEFI
Filing DateTuesday, July 23, 2019
Status700 - REGISTERED
Status DateTuesday, May 26, 2020
Registration Number6061129
Registration DateTuesday, May 26, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 10, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use, namely, for the treatment of diabetes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 4, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTaisho Pharmaceutical Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameTaisho Pharmaceutical Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameTaisho Pharmaceutical Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Monday, December 5, 2022INTERNATIONAL REGISTRATION RENEWED
Saturday, December 12, 2020TOTAL INVALIDATION PROCESSED BY THE IB
Saturday, October 10, 2020FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, September 22, 2020FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, September 22, 2020FINAL DISPOSITION PROCESSED
Wednesday, August 26, 2020FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, July 17, 2020NOTIFICATION PROCESSED BY IB
Tuesday, May 26, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, March 10, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 10, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 19, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 19, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, February 19, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 3, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 9, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 9, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 9, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 8, 2019REFUSAL PROCESSED BY IB
Thursday, October 10, 2019NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, October 10, 2019REFUSAL PROCESSED BY MPU
Sunday, September 29, 2019NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, September 28, 2019NON-FINAL ACTION WRITTEN
Thursday, September 26, 2019ASSIGNED TO EXAMINER
Tuesday, September 10, 2019APPLICATION FILING RECEIPT MAILED
Wednesday, September 4, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, August 22, 2019SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

Related Keywords

lusefi treatment diabetes namely human preparations pharmaceutical